In This Article:
-
Revenue Growth: 9% increase in constant currency, 4% in reported currency.
-
Normalized EBITDA: Up 21% in constant exchange rate (CER), 12% in reported currency.
-
Gross Margin: Growth above 20%.
-
Normalized Headline Earnings Per Share: Increased by 17% to ZAR7.24.
-
Commercial Pharma Revenue: Double-digit growth in both revenue and EBITDA.
-
Manufacturing Revenue: 0% growth reported, but 20% underlying growth excluding heparin.
-
FDF Growth: 65% increase over the first half of the previous year.
-
Operating Cash Flow Conversion Rate: Forecast to exceed 100%.
-
Effective Tax Rate: Increased to 21.6% for normalized tax rate.
-
Interest Rate: Effective interest rate around 5%, expected to decrease in the second half.
-
Working Capital: 50% of revenue, expected to reduce to 45% by year-end.
-
Currency Impact: Significant impact with a 12% delta in normalized earnings between reported and CER.
Release Date: March 04, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Aspen Pharmacare Holdings Ltd (APNHY) achieved double-digit growth in revenue and EBITDA in its Commercial Pharma segment, indicating strong operational performance.
-
The company successfully derisked its Commercial Pharma business by addressing challenges in China and Russia, leading to a more stable base for growth.
-
Aspen's Manufacturing segment saw normalized EBITDA more than double, despite no growth in turnover, due to strategic shifts like the heparin toll model.
-
The company is making significant progress in the GLP-1 space, with expectations for early market entry and substantial future growth opportunities.
-
Aspen anticipates strong CER growth in EBITDA and operating cash flow conversion rates exceeding 100%, demonstrating robust financial health.
Negative Points
-
Currency fluctuations had a significant negative impact on reported financial results, with a notable delta between reported and constant exchange rate figures.
-
The company faces elevated working capital levels due to seasonal inventory builds and the integration of the Sandoz China business, impacting cash flow.
-
Aspen's effective tax rate increased significantly, driven by higher contributions from sterile manufacturing in high-tax jurisdictions and new global tax regulations.
-
The business environment in China remains challenging, necessitating a larger-than-anticipated restructuring effort.
-
Interest rates have peaked, impacting finance costs, although a reduction is anticipated in the second half of the fiscal year.